Comparison of Citaloperam with Venlafaxine in Treatment of Atypical Depression

Document Type : Original Article


1 Associate Professor of Psychiatry.Department of Psychiatry, University ofWelfare and Rehabilitation Sciences, Tehran,Iran.

2 Assistant Professor ofPsychiatry.Department of Psychiatry, University ofWelfare and Rehabilitation Sciences, Tehran,Iran.

3 Psychiatrist.Department of Psychiatry, University ofWelfare and Rehabilitation Sciences, Tehran,Iran.


Background and Objective: This study conducted to compare effectiveness of citalopram with venlafaxine in treatment of outpatients with atypical depression.
Subjects and Methods: The present study was an open-label randomized clinical trial, and compared the effectiveness of citalopram with venlafaxine in 80 outpatients with mild to moderate atypical depression based on DSM-IV-TR criteria using Beck depression questionnaire, who visited Akhavan clinic and Razi Psychiatric Hospital in Shahre Rey, Tehran. Evaluation of symptoms improvement and incidence of side effects were carried out fortnightly with the use of a clinical interview or by telephone up to eight weeks.
Results: Although venlafaxine group showed more decline in Beck scores, statistical analysis of the results showed no significant differences in declined Beck scores in citalopram group (with the mean score of 6.42 ± 11.78) versus venlafaxine group (with the  mean score of 7.87± 8.03 ) (P=0.522).
Conclusion: Both citalopram and venlafaxine were effective in atypical depression treatment, and no significant difference was found. However venlafaxine was more effective in reduction of sleep duration and caused weight loss.


1-Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, "et al". Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression.AHRQ Comparative Effectiveness Reviews2007Jan: 07-EHC007-EF.

2-Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54(11): 405-18.
3-Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996 Nov 1; 274(5288): 740-3.
4-Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ. The treatment of chronic depression, Part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry1998 Nov; 59(11): 608-19.
5-Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population.Am J Psychiatry 1996 Nov; 153(11): 1411-7.
6-Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry1997 Nov; 54(11): 989-91.

7-Rush AJ, Trivedi MH.Treating Depression to Remission.Psychiatric Annals 1997Dec; 25(12): 704-9.

8-Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three-to 5-year prospective follow-up of outcome in major depression. Psychol Med 1998 May; 28(3): 731-5.
9-Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000 May; 57(5): 425-34.
10-Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. J Clin Psychiatry 1998; (59 Suppl18): 5-9.
11-Thase M. Antidepressant treatment of atypical depression.  Acta Psychiatr Scand 1997 , 95:424.
12-Stewart JW, McGrath PJ, Quitkin FM. Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features?Neuropsychopharmacology 2002 Feb; 26(2):237-45.
13-Stewart JW, Quitkin FM, McGrath PJ, Klein DF. Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions. J Affect Disord 2005 Jun; 86(2-3): 161-7.
14-Levitan RD, Vaccarino FJ, Brown GM, Kennedy SH. Low-dose dexamethasone challenge in women with atypical major depression: pilot study. J Psychiatry Neurosci 2002 Jan; 27(1): 47-51.
15-McGinn LK, Asnis GM, Rubinson E. Biological and clinical validation of atypical depression.Psychiatry Res 1996 Mar 29; 60(2-3): 191-8.
16-Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999 Mar; 4(2): 182-8.
17-Agosti V, Stewart JW. Atypical and non-atypical subtypes of depression: comparison of social functioning, symptoms, course of illness, co-morbidity and demographic features. J Affect Disord 2001 Jun; 65(1): 75-9.
18-Angst J, Gamma A, Sellaro R, Zhang H, Merikangas K. Toward validation of atypical depression in the community: results of theZurich cohort study. J Affect Disord 2002 Nov; 72(2): 125-38.
19-Benazzi F. Is there a link between atypical and early-onset. Compr Psychiatry 2003 Mar-Apr; 44(2): 102-9.
20-Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression withatypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 003 Aug; 60(8): 817-26.
21-Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotoninreuptake inhibitors. Br J Psychiatry 2001 Mar; 178: 234-41.
22-Cannon M. Highlights of this issue. Br J Psychiatry 2001Feb; 178: 192-4.
23-Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004 Feb 1; 55(3): 296-300.
24-Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992 Oct; 161: 562-5.
25-Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experimentsin humans. Pharmacopsychiatry 1996 Jan; 29(1): 2-11.
26-Smith D, Dempster C, Glanville J, Freemantle N, Anderson I.  Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002 May; 180: 396-404.
27-Li XX, Liu Q, Liu XM, Shi HW, Chen SF. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Microb Cell Fact 2016 Feb 20; 15(1): 43.
28-Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, "et al". Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression. JAMA 2008 Feb 27;299(8):901-13. doi: 10.1001/jama.299.8.901.
29-Roose SP, Miyazaki M, Devanand D, Seidman S, Fitzsimmons L, Turret N, "et al". An open trial of venlafaxinefor the treatment of late‐life atypical depression. Int J Geriatr Psychiatry 2004 Oct;19(10):989-94.
30-Kennedy S H, Andersen H F, Lam RW.  Efficacy of escitalopram in the treatment of major depressive disordercompared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. JPsychiatry Neurosci 2006; 31(2): 122-31.
31-Quitkin FM, McGrath PJ, Stewart JW, Klein DF. A reappraisal of atypical depression.Am J Psychiatry 2003 Apr; 160(4): 798-800.
32-Mcgrath PJ, Srewart J W, Janal MN, Petkova E, Quitkin FM,  Klein DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatmentof atypical depression. Am J Psychiatry 2000 Mar; 157(3): 344-50.
33-Sotsky SM, Simmens SJ.Pharmacotherapy response and diagnostic validity in atypical depression.J Affect Disord 1999 Aug; 54(3): 237-47.